Trastuzumab-NH-PEG8-VC-PAB-MMAE

Trastuzumab-NH-PEG8-VC-PAB-MMAE is an antibody-drug conjugate (ADC) of Anti-Her2 human monoclonal antibody (Trastuzumab) with MMAE (Monomethyl auristatin E) through a cathepsin cleavable peptide linker (-VC-PAB-) on antibody Fc portion site-specific on Q295 by microbial transglutaminase (mTG). MMAE is a synthetic antineoplastic agent. It is also a microtubule-disrupting agent. The DAR of Trastuzumab-NH-PEG8-VC-PAB-MMAE is about 1.5. >98% of antibody is conjugated. This product is used for research only. It can be used as a reference compound.

Product Details
Species Reactivity	Human
Host/Isotype	Cell culture/ IgG1
Class	Monoclonal
Type	Antibody-Drug conjugate
Immunogen	Human Her2
DAR (Drug to Antibody Ratio)	>1.5, >98% Ab is conjugated
Clone	Trastuzumab biosimilar
Conjugate	Trastuzumab conjugated with NH2-PEG8-VC-PAB-MMAE
Purity	>98%
Molecular Weight	~150kDa
Protein Concentration	2 mg/ml
Formulation	Lyophilized
Storage Condition	4°C for short time, -20°C or -80°C for long time.
Storage Buffer	50 mM Sodium Phosphate, 6% Trehalose, pH7.0